QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)

Stoke Therapeutics - STOK Price Target & Analyst Ratings

$9.96
+0.44 (+4.62%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$9.53
$10.00
50-Day Range
$7.07
$10.38
52-Week Range
$6.88
$26.60
Volume
124,397 shs
Average Volume
299,330 shs
Market Capitalization
$392.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.71

Stoke Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 7 Analyst Ratings

Consensus Analyst Price Target

$28.71
188.30% Upside
High Prediction$50.00
Average Prediction$28.71
Low Prediction$9.00
TypeCurrent
1/31/22 to 1/31/23
1 Month Ago
1/1/22 to 1/1/23
3 Months Ago
11/2/21 to 11/2/22
1 Year Ago
1/31/21 to 1/31/22
Consensus Rating
Moderate Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$28.71$34.00$42.71$52.14
Predicted Upside188.30% Upside167.54% Upside122.03% Upside74.74% Upside
Get Stoke Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.


STOK Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

STOK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Stoke Therapeutics Stock vs. The Competition

TypeStoke TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.71
2.65
2.46
Consensus RatingModerate BuyBuyHold
Predicted Upside201.62% Upside957.95% Upside10.99% Upside
News Sentiment RatingVery Positive News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/11/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$38.00 ➝ $32.00+265.30%
1/6/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Underperform$22.00 ➝ $9.00+5.51%
12/5/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$70.00 ➝ $35.00+375.54%
11/15/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$38.00 ➝ $20.00+114.36%
11/14/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$50.00 ➝ $25.00+157.20%
10/24/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Rudy Li
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$30.00+126.24%
1/31/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$50.00+178.86%
11/22/2021JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight$41.00+47.48%
5/18/2021UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$35.00-0.54%
5/10/2021Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chico
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform
11/13/2020BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$46.00 ➝ $68.00+53.99%
3/23/2020Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
(Data available from 1/31/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












STOK Price Target - Frequently Asked Questions

What is Stoke Therapeutics's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Stoke Therapeutics stock is Moderate Buy based on the current 1 sell rating and 6 buy ratings for STOK. The average twelve-month price prediction for Stoke Therapeutics is $28.71 with a high price target of $50.00 and a low price target of $9.00. Learn more on STOK's analyst rating history.

Do Wall Street analysts like Stoke Therapeutics more than its competitors?

Analysts like Stoke Therapeutics more than other Medical companies. The consensus rating for Stoke Therapeutics is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how STOK compares to other companies.

Is Stoke Therapeutics being downgraded by Wall Street analysts?

Over the previous 90 days, Stoke Therapeutics's stock had 1 downgrade by analysts.

Does Stoke Therapeutics's stock price have much upside?

According to analysts, Stoke Therapeutics's stock has a predicted upside of 165.78% based on their 12-month price targets.

What analysts cover Stoke Therapeutics?

Stoke Therapeutics has been rated by Bank of America, Cantor Fitzgerald, Credit Suisse Group, HC Wainwright, and Needham & Company LLC in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:STOK) was last updated on 1/31/2023 by MarketBeat.com Staff